255 related articles for article (PubMed ID: 36724193)
21. The Effects of Pharmacological Urate-Lowering Therapy on Cardiovascular Disease in Older Adults with Gout.
Gerritsen M; Nurmohamed MT
Drugs Aging; 2024 Apr; 41(4):319-328. PubMed ID: 38416394
[TBL] [Abstract][Full Text] [Related]
22. Comparative efficacy and safety of uricosuric agents in the treatment of gout or hyperuricemia: a systematic review and network meta-analysis.
Li YJ; Chen LR; Yang ZL; Wang P; Jiang FF; Guo Y; Qian K; Yang M; Yin SJ; He GH
Clin Rheumatol; 2023 Jan; 42(1):215-224. PubMed ID: 36036279
[TBL] [Abstract][Full Text] [Related]
23. Expert opinion on emerging urate-lowering therapies.
Stamp LK; Merriman TR; Singh JA
Expert Opin Emerg Drugs; 2018 Sep; 23(3):201-209. PubMed ID: 30244605
[TBL] [Abstract][Full Text] [Related]
24. Effects of vitamin C supplementation on gout risk: results from the Physicians' Health Study II trial.
Juraschek SP; Gaziano JM; Glynn RJ; Gomelskaya N; Bubes VY; Buring JE; Shmerling RH; Sesso HD
Am J Clin Nutr; 2022 Sep; 116(3):812-819. PubMed ID: 35575611
[TBL] [Abstract][Full Text] [Related]
25. The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
Jackson RL; Hunt B; MacDonald PA
BMC Geriatr; 2012 Mar; 12():11. PubMed ID: 22436129
[TBL] [Abstract][Full Text] [Related]
26. Cardiovascular Safety of Urate Lowering Therapies.
Kang EH; Kim SC
Curr Rheumatol Rep; 2019 Jul; 21(9):48. PubMed ID: 31342190
[TBL] [Abstract][Full Text] [Related]
27. Real-world treatment of gout and asymptomatic hyperuricemia: A cross-sectional study of Japanese health insurance claims data.
Koto R; Nakajima A; Horiuchi H; Yamanaka H
Mod Rheumatol; 2021 Jan; 31(1):261-269. PubMed ID: 32552370
[TBL] [Abstract][Full Text] [Related]
28. GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease.
Torres RJ; Puig JG
Int J Rheum Dis; 2018 Jun; 21(6):1270-1276. PubMed ID: 29879316
[TBL] [Abstract][Full Text] [Related]
29. Association Between Gut Microbiota and Elevated Serum Urate in Two Independent Cohorts.
Wei J; Zhang Y; Dalbeth N; Terkeltaub R; Yang T; Wang Y; Yang Z; Li J; Wu Z; Zeng C; Lei G
Arthritis Rheumatol; 2022 Apr; 74(4):682-691. PubMed ID: 34725964
[TBL] [Abstract][Full Text] [Related]
30. [Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia].
Fujimori S
Nihon Rinsho; 2008 Apr; 66(4):729-35. PubMed ID: 18409523
[TBL] [Abstract][Full Text] [Related]
31. [Gout and cardiovascular risk].
Němec P
Vnitr Lek; 2014 Oct; 60(10):893-901. PubMed ID: 25382012
[TBL] [Abstract][Full Text] [Related]
32. The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale.
Saddekni MB; Saag KG; Dudenbostel T; Oparil S; Calhoun DA; Sattui SE; Feig DI; Muntner P; Redden DT; Foster PJ; Rahn EJ; Biggers SR; Li P; Gaffo AL
Contemp Clin Trials; 2016 Sep; 50():238-44. PubMed ID: 27587282
[TBL] [Abstract][Full Text] [Related]
33. Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline.
Shekelle PG; Newberry SJ; FitzGerald JD; Motala A; O'Hanlon CE; Tariq A; Okunogbe A; Han D; Shanman R
Ann Intern Med; 2017 Jan; 166(1):37-51. PubMed ID: 27802478
[TBL] [Abstract][Full Text] [Related]
34. The comparative effect of exposure to various risk factors on the risk of hyperuricaemia: diet has a weak causal effect.
Topless RKG; Major TJ; Florez JC; Hirschhorn JN; Cadzow M; Dalbeth N; Stamp LK; Wilcox PL; Reynolds RJ; Cole JB; Merriman TR
Arthritis Res Ther; 2021 Mar; 23(1):75. PubMed ID: 33663556
[TBL] [Abstract][Full Text] [Related]
35. Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis.
Li S; Yang H; Guo Y; Wei F; Yang X; Li D; Li M; Xu W; Li W; Sun L; Gao Y; Wang Y
Sci Rep; 2016 Sep; 6():33082. PubMed ID: 27605442
[TBL] [Abstract][Full Text] [Related]
36. [Gout].
Tausche AK
Internist (Berl); 2021 May; 62(5):513-525. PubMed ID: 33721041
[TBL] [Abstract][Full Text] [Related]
37. Identification of Two Dysfunctional Variants in the ABCG2 Urate Transporter Associated with Pediatric-Onset of Familial Hyperuricemia and Early-Onset Gout.
Toyoda Y; Pavelcová K; Bohatá J; Ješina P; Kubota Y; Suzuki H; Takada T; Stiburkova B
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669292
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database.
Ito S; Torii T; Nakajima A; Iijima T; Murano H; Horiuchi H; Yamanaka H; Honda M
BMC Pediatr; 2020 Oct; 20(1):481. PubMed ID: 33059648
[TBL] [Abstract][Full Text] [Related]
39. New therapeutic approach to hyperuricemia and gout in the light of recommendations.
Lioté F
Joint Bone Spine; 2016 Jul; 83(4):376-80. PubMed ID: 27085801
[No Abstract] [Full Text] [Related]
40. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
Cutolo M; Cimmino MA; Perez-Ruiz F
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
